Active Not Recruiting PHASE3 INTERVENTIONAL 3-arm NCT05113251

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)

Sponsor: AstraZeneca

Conditions Breast Cancer Breast Neoplasms HER2-positive Early Breast Cancer

Interventions Doxorubicin Paclitaxel Pertuzumab Trastuzumab Trastuzumab Deruxtecan cyclophosphamide

Updated 35 times since 2021 Last updated: Feb 20, 2026 Started: Oct 25, 2021 Primary completion: Mar 12, 2025 Completion: Apr 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Breast Cancer and Breast Neoplasms and is currently ongoing. AstraZeneca leads this study, which shows 35 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

35 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE3
Dec 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 30 earlier versions

Jun 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Mar 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE3
Dec 2024 — Mar 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE3
May 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Jan 2024 [monthly]

Recruiting PHASE3
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE3

Status: Active Not Recruiting → Recruiting
Sep 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE3
Jul 2023 — Sep 2023 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
May 2023 — Jul 2023 [monthly]

Recruiting PHASE3
Apr 2023 — May 2023 [monthly]

Recruiting PHASE3
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE3
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE3
May 2022 — Jun 2022 [monthly]

Recruiting PHASE3
Apr 2022 — May 2022 [monthly]

Recruiting PHASE3
Feb 2022 — Apr 2022 [monthly]

Recruiting PHASE3
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE3
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE3

First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Daiichi Sankyo

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augsburg, Germany , Bacolod, Philippines , Bangkok, Thailand , Barcelona, Spain , Beijing, China , Berlin, Germany , Beverly Hills, United States , Bialystok, Poland , Biała Podlaska, Poland , Bologna, Italy and 109 more locations